Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners12.3.2026 11:00:00 CET | Press release
AI technology meets on-the-ground expertise from leading organizations across five continents, accessible to billions of consumers in 50+ languages covering 97% of global internet users. AMSTERDAM, NL / ACCESS Newswire / March 12, 2026 / The Global Anti-Scam Alliance (GASA) launched today Scam.org, an AI-powered platform that provides scam education, prevention, detection, reporting, and victim support in over 50 languages, making it a new global hub, accessible to 97% of the world's internet users. Scam.org is powered by partnerships with OpenAI and leading cybersecurity organizations, AnyTech365, CUBE AI,Falkin, Malwarebytes, Netcraft, ReasonLabs, ScamAdviser, Scamnetic, Seraph Secure and Spamhaus. For personal victim support, Scam.org collaborates with other victim support organizations such as AARPin the USA and ANVINT in Brazil. The platform expects more organizations to join, with plans to build an even stronger and broader coalition, creating a world where people are safer from
LiberNovo: From Spring Cleaning to Physical Renewal12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / As the annual ritual of spring cleaning approaches, a new movement in functional design is shifting the focus from tidying desks to restoring the bodies that sit at them. LiberNovo, a pioneer in health-first design, has announced its spring initiative: a fundamental reimagining of the smart workspace that prioritizes physical fluidity over static organization. New Season, New Standards For decades, office chair ergonomics centered on the "90-degree rule"-a rigid posture that modern research suggests is counterproductive. The true culprit of office fatigue isn't just sitting; it is the lack of movement. Prolonged static positions compress the spine and reduce circulation. LiberNovo's philosophy asserts that a "Spring Reset" is incomplete if it only addresses surface-level clutter while leaving the body in a state of constant strain. Engineering Movement At the core of this movement is the LiberNovo Omni, a chair designed to master Dynam
LiberNovo Omni Wins iF DESIGN AWARD 2026 for Breakthrough Ergonomic Design12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / LiberNovo is proud to announce that its leading product, the LiberNovo Omni, has won the prestigious iF DESIGN AWARD 2026 in the Product Design - Beauty/Wellness category. The iF DESIGN AWARD is one of the most esteemed design competitions in the world, honoring outstanding design achievements in terms of innovation, functionality, and user experience. Developed to revolutionize the experience of sitting for long periods, the LiberNovo Omni is a product that creates a new category of seating solutions: the Dynamic Ergonomic Chair. The chair doesn't lock people into fixed positions; it accommodates natural body positions and movement throughout the day. This award-winning chair features intelligent ergonomic technologies to enhance user comfort, spinal health, and support movement. These include LiberNovo's innovative Dynamic Support, which automatically adjusts to changing postures, and an adjustable ergonomic framework designed to ens
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference11.3.2026 17:00:00 CET | Press release
Liquid-Cooled Desktop System Runs Models up to 120B Parameters Locally With a Fully Open-Source Stack, Starting at $9,999 SANTA CLARA, CA / ACCESS Newswire / March 11, 2026 / Tenstorrent, the AI computing company led by CEO Jim Keller, today announced TT-QuietBox™ 2 (Blackhole™). This whisper-quiet, liquid-cooled AI workstation runs models up to 120 billion parameters directly at your desk, ships with an entirely open-source software stack from compiler to kernel, and starts at $9,999. It marks the industry's first desktop AI workstation built on RISC-V architecture to deliver teraflop-class inference. The Inference Imperative The timing matters. Inference has quietly overtaken training as the dominant AI workload, now accounting for more than 55% of cloud AI infrastructure spending at $37.5 billion - and it is still accelerating. Yet, developers running these workloads face a stark choice: pay per-token cloud fees that compound as usage scales, or buy hardware locked to proprietary st
Clockwork.io Introduces A New Class of Fault Tolerance to End Failure-Driven GPU Waste in AI Training11.3.2026 14:00:00 CET | Press release
New TorchPass solution addresses a multi-million dollar challenge with AI infrastructure; uses Live GPU Migration to keep large-scale AI training running through hardware failures instead of forcing costly restarts PALO ALTO, CA / ACCESS Newswire / March 11, 2026 / Clockwork.io, the leader in Software-Driven AI Fabrics™- a programmable, vendor-neutral software layer that optimizes large-scale GPU clusters for real-time observability, fault tolerance, and deterministic performance-today announced the general availability of TorchPass Workload Fault Tolerance. This new class of software-driven fault-tolerance eliminates one of the most costly failure modes in large-scale AI training: catastrophic job restarts caused by infrastructure faults. Delivered as a core capability of the Clockwork.io FleetIQ™ platform, TorchPass applies the principles of Software-Driven AI Fabrics to distributed training, using Live GPU Migration to allow workloads to continue running through GPU failures, networ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom